{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:12:27Z","timestamp":1760548347459},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,9,27]],"date-time":"2006-09-27T00:00:00Z","timestamp":1159315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2007,1,12]]},"DOI":"10.1007\/s10928-006-9032-2","type":"journal-article","created":{"date-parts":[[2006,9,26]],"date-time":"2006-09-26T18:21:36Z","timestamp":1159294896000},"page":"35-55","source":"Crossref","is-referenced-by-count":7,"title":["Improving Data Reliability Using a Non-Compliance Detection Method versus Using Pharmacokinetic Criteria"],"prefix":"10.1007","volume":"34","author":[{"given":"Smita A.","family":"Kshirsagar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrence F.","family":"Blaschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis B.","family":"Sheiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Krygowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Verotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,9,27]]},"reference":[{"key":"9032_CR1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/A:1011582713692","volume":"28","author":"J. Lu","year":"2001","unstructured":"Lu J., Gries J.M., Verotta D., Sheiner L.B. (2001) Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J. Pharmacokinet. Pharmacodyn. 28:343\u2013362","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"9032_CR2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev.pharmtox.40.1.67","volume":"40","author":"L.B. Sheiner","year":"2000","unstructured":"Sheiner L.B., Steimer J.L. (2000). Pharmacokinetic\/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 40:67\u201395","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"9032_CR3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/j.1552-4604.1994.tb03974.x","volume":"34","author":"C.C. Peck","year":"1994","unstructured":"Peck C.C., Barr W.H., Benet L.Z., Collins J., Desjardins R.E., Furst D.E., Harter J.G., Levy G., Ludden T., Rodman J.H. (1994). Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug J. Clin. Pharmacol. 34:111\u2013119","journal-title":"Clin. Pharmacol."},{"key":"9032_CR4","unstructured":"Guidance for Industry on Population Pharmacokinetics (1999). Available at: http:\/\/www.fda.gov\/cder\/guidance\/1852fnl.pdf"},{"key":"9032_CR5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF00226323","volume":"49","author":"L. Aarons","year":"1996","unstructured":"Aarons L., Balant L.P., Mentre F., Morselli P.L., Rowland M., Steimer J.L., Vozeh S. (1996). Practical experience and issues in designing and performing population pharmacokinetic\/pharmacodynamic studies. Eur. J. Clin. Pharmacol. 49:251\u2013254","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"9032_CR6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/096228029900800305","volume":"8","author":"B. Vrijens","year":"1999","unstructured":"Vrijens B., Goetghebeur E. (1999). The impact of compliance in pharmacokinetic studies. Stat. Methods Med. Res. 8:247\u2013262","journal-title":"Stat. Methods Med. Res."},{"key":"9032_CR7","first-page":"202","volume":"27","author":"J. Urquhart","year":"1994","unstructured":"Urquhart J. (1994). Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin. Pharmacokinet. 27:202\u2013215","journal-title":"A review of recent research. Clin. Pharmacokinet."},{"key":"9032_CR8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2710.1992.tb01306.x","volume":"17","author":"L.S. Morris","year":"1992","unstructured":"Morris L.S., Schulz R.M. (1992). Patient compliance \u2013 an overview. J. Clin. Pharm. Ther. 17:283\u2013295","journal-title":"J. Clin. Pharm. Ther."},{"key":"9032_CR9","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2313::AID-SIM935>3.0.CO;2-V","volume":"17","author":"P. Girard","year":"1998","unstructured":"Girard P., Blaschke T.F., Kastrissios H., Sheiner L.B. (1998). A Markov mixed effect regression model for drug compliance. Stat. Med. 17:2313\u20132333","journal-title":"Stat. Med."},{"key":"9032_CR10","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1002\/sim.1830","volume":"23","author":"L.A. Kenna","year":"2004","unstructured":"Kenna L.A., Sheiner L.B. (2004). Estimating treatment effect in the presence of non-compliance measured with error: precision and robustness of data analysis methods. Stat. Med. 23:3561\u20133580","journal-title":"Stat. Med."},{"key":"9032_CR11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clpt.2004.07.010","volume":"76","author":"D. Soy","year":"2004","unstructured":"Soy D., Beal S.L., Sheiner L.B. (2004). Population one-compartment pharmacokinetic analysis with missing dosage data. Clin. Pharmacol. Ther. 76:441\u2013451","journal-title":"Clin. Pharmacol. Ther."},{"key":"9032_CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1023297426153","volume":"30","author":"S. Mu","year":"2003","unstructured":"Mu S., Ludden T.M. (2003). Estimation of population pharmacokinetic parameters in the presence of non-compliance. J. Pharmacokinet. Pharmacodyn. 30:53\u201381","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"9032_CR13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/sim.1401","volume":"22","author":"T.R. Ten Have","year":"2003","unstructured":"Ten Have T.R., Joffe M., Cary M. (2003). Causal logistic models for non-compliance under randomized treatment with univariate binary response. Stat. Med. 22:1255\u20131283","journal-title":"Stat. Med."},{"key":"9032_CR14","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/sim.741","volume":"20","author":"T. Sato","year":"2001","unstructured":"Sato T. (2001). A method for the analysis of repeated binary outcomes in randomized clinical trials with non-compliance. Stat. Med. 20:2761\u20132774","journal-title":"Stat. Med."},{"key":"9032_CR15","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/(SICI)1097-0258(19991115)18:21<2879::AID-SIM190>3.0.CO;2-K","volume":"18","author":"P.A. Korhonen","year":"1999","unstructured":"Korhonen P.A., Laird N.M., Palmgren J. (1999). Correcting for non-compliance in randomized trials: an application to the ATBC Study. Stat. Med. 18:2879\u20132897","journal-title":"Stat. Med."},{"key":"9032_CR16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1023\/A:1012184808192","volume":"14","author":"E.N. Jonsson","year":"1997","unstructured":"Jonsson E.N., Wade J.R., Almqvist G., Karlsson M.O. (1997). Discrimination between rival dosing histories. Pharm. Res. 14:984\u2013991","journal-title":"Pharm. Res."},{"key":"9032_CR17","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1097\/00002030-200311070-00009","volume":"17","author":"R.M. Gulick","year":"2003","unstructured":"Gulick R.M., Meibohm A., Havlir D., Eron J.J., Mosley A., Chodakewitz J.A., Isaacs R., Gonzalez C., McMahon D., Richman D.D., Robertson M., Mellors J.W. (2003). Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. Aids 17:2345\u20132349","journal-title":"Aids"},{"key":"9032_CR18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00041552-200009000-00003","volume":"9","author":"A.J. Olyaei","year":"2000","unstructured":"Olyaei A.J., deMattos A.M., Bennett W.M. (2000). Renal toxicity of protease inhibitors. Curr. Opin. Nephrol. Hypertens. 9:473\u2013476","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"9032_CR19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0090-4295(97)00401-9","volume":"50","author":"D.L. Gentle","year":"1997","unstructured":"Gentle D.L., Stoller M.L., Jarrett T.W., Ward J.F., Geib K.S., Wood A.F. (1997). Protease inhibitor-induced urolithiasis. Urology 50:508\u2013511","journal-title":"Urology"},{"key":"9032_CR20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0090-4295(97)00399-3","volume":"50","author":"R.G. Bruce","year":"1997","unstructured":"Bruce R.G., Munch L.C., Hoven A.D., Jerauld R.S., Greenburg R., Porter W.H., Rutter P.W. (1997). Urolithiasis associated with the protease inhibitor indinavir. Urology 50:513\u2013518","journal-title":"Urology"},{"key":"9032_CR21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00002030-199903110-00005","volume":"13","author":"J.P. Dieleman","year":"1999","unstructured":"Dieleman J.P., Gyssens I.C., van der Ende M.E., de Marie S., Burger D.M. (1999). Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. Aids 13:473\u2013478","journal-title":"Aids"},{"key":"9032_CR22","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archinte.162.13.1493","volume":"162","author":"J.P. Dieleman","year":"2002","unstructured":"Dieleman J.P., Sturkenboom M.C., Jambroes M., Gyssens I.C., Weverling G.J., ten Veen J.H., Schrey G., Reiss P., Stricker B.H. (2002). Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch. Intern. Med. 162:1493\u20131501","journal-title":"Arch. Intern. Med."},{"key":"9032_CR23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00126334-200302010-00004","volume":"32","author":"J.P. Dieleman","year":"2003","unstructured":"Dieleman J.P., van Rossum A.M., Stricker B.C., Sturkenboom M.C., de Groot R., Telgt D., Blok W.L., Burger D.M., Blijenberg B.G., Zietse R., Gyssens I.C. (2003). Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J. Acquir. Immune. Defic. Syndr. 32:135\u20131427D","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"9032_CR24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1086\/520226","volume":"29","author":"E. Martinez","year":"1999","unstructured":"Martinez E., Leguizamon M., Mallolas J., Miro J.M., Gatell J.M. (1999). Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin. Infect. Dis. 29:422\u2013425","journal-title":"Clin. Infect. Dis."},{"key":"9032_CR25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0022-5347(05)66911-X","volume":"164","author":"E. Saltel","year":"2000","unstructured":"Saltel E., Angel J.B., Futter N.G., Walsh W.G., O\u2019Rourke K., Mahoney J.E. (2000). Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J. Urol. 164:1895\u20131897","journal-title":"J. Urol."},{"key":"9032_CR26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00126334-200204010-00008","volume":"29","author":"C. Solas","year":"2002","unstructured":"Solas C., Basso S., Poizot-Martin I., Ravaux I., Gallais H., Gastaut J.A., Durand A., Lacarelle B. (2002). High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800\/100\u00a0mg twice-daily regimen. J. Acquir. Immune. Defic. Syndr. 29:374\u2013377","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"9032_CR27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00005392-199707000-00007","volume":"158","author":"S.E. Sutherland","year":"1997","unstructured":"Sutherland S.E., Reigle M.D., Seftel A.D., Resnick M.I. (1997). Protease inhibitors and urolithiasis. J. Urol. 158:31\u201333","journal-title":"J. Urol."},{"key":"9032_CR28","first-page":"256","volume":"122","author":"L.D. Trainor","year":"1998","unstructured":"Trainor L.D., Steinberg J.P., Austin G.W., Solomon H.M. (1998). Indinavir identification of patients at increased risk of developing nephrotoxicity. Arch. Pathol. Lab. Med. 122:256\u2013259","journal-title":"Arch. Pathol. Lab. Med."},{"key":"9032_CR29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/ajkd.2000.9791","volume":"36","author":"R.F. Gagnon","year":"2000","unstructured":"Gagnon R.F., Tecimer S.N., Watters A.K., Tsoukas C.M. (2000). Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am. J. Kidney Dis. 36:507\u2013515","journal-title":"Am. J. Kidney Dis."},{"key":"9032_CR30","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/339486","volume":"34","author":"J.B. Kopp","year":"2002","unstructured":"Kopp J.B., Falloon J., Filie A., Abati A., King C., Hortin G.L., Mican J.M., Vaughan E., Miller K.D. (2002). Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin. Infect. Dis. 34:1122\u20131128","journal-title":"Clin. Infect. Dis."},{"key":"9032_CR31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/0003-4819-127-2-199707150-00004","volume":"127","author":"J.B. Kopp","year":"1997","unstructured":"Kopp J.B., Miller K.D., Mican J.A., Feuerstein I.M., Vaughan E., Baker C., Pannell L.K., Falloon J. (1997). Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. 127:119\u2013125","journal-title":"Ann. Intern. Med."},{"key":"9032_CR32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01059771","volume":"21","author":"J.R. Wade","year":"1993","unstructured":"Wade J.R., Kelman A.W., Howie C.A., Whiting B. (1993). Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J. Pharmacokinet. Biopharm. 21:209\u2013222","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"9032_CR33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1023\/A:1022972420004","volume":"29","author":"P.O. Gisleskog","year":"2002","unstructured":"Gisleskog P.O., Karlsson M.O., Beal S.L. (2002). Use of prior information to stabilize a population data analysis. J. Pharmacokinet. Pharmacodyn. 29:473\u2013505","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"9032_CR34","volume-title":"NONMEM Users Guide, NONMEM Project Group","year":"1992","unstructured":"Beal S.L., Sheiner L.B.(eds) (1992). NONMEM Users Guide, NONMEM Project Group. University of California at San Francisco, San Francisco"},{"key":"9032_CR35","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/318820","volume":"183","author":"R.M. Gulick","year":"2001","unstructured":"Gulick R.M., Smeaton L.M., D\u2019Aquila R.T., Eron J.J., Currier J.S., Gerber J.G., Acosta E., Sommadossi J.P., Tung R., Snyder S., Kuritzkes D.R., Murphy R.L. (2001). Indinavir, nevirapine, stavudine, and lamivudine for human virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. J. Infect. Dis. 183:715\u2013721","journal-title":"J. Infect. Dis."},{"key":"9032_CR36","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.48.3.918-923.2004","volume":"48","author":"R. DiCenzo","year":"2004","unstructured":"DiCenzo R., Forrest A., Fischl M.A., Collier A., Feinberg J., Ribaudo H., DiFrancecso R., Morse G.D. (2004). Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects. Antimicrob. Agents 48:918\u2013923","journal-title":"Antimicrob. Agents"},{"key":"9032_CR37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/377311","volume":"188","author":"M.A. Fischl","year":"2003","unstructured":"Fischl M.A., Ribaudo H.J., Collier A.C., Erice A., Giuliano M., Dehlinger M., Eron J.J., Jr., Saag M.S., Hammer S.M., Vella S., Morse G.D., Feinberg J.E., Denter L.M., Eshleman S.H. (2003). A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J. Infect. Dis. 188:625\u2013634","journal-title":"J. Infect. Dis."},{"key":"9032_CR38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1067\/mcp.2002.126183","volume":"72","author":"M. Pfister","year":"2002","unstructured":"Pfister M., Labbe L., Lu J.F., Hammer S.M., Mellors J., Bennett K.K., Rosenkranz S. (2002). Sheiner L.B. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin. Pharmacol. Ther. 72:133\u2013141","journal-title":"Clin. Pharmacol. Ther."},{"key":"9032_CR39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/AAC.47.1.130-137.2003","volume":"47","author":"M. Pfister","year":"2003","unstructured":"Pfister M., Labbe L., Hammer S.M., Mellors J., Bennett K.K., Rosenkranz S., Sheiner L.B. (2003). Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob. Agents Chemother. 47:130\u2013137","journal-title":"Antimicrob. Agents Chemother."},{"key":"9032_CR40","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/00126334-200411010-00004","volume":"37","author":"E.P. Acosta","year":"2004","unstructured":"Acosta E.P., Wu H., Hammer S.M., Yu S., Kuritzkes D.R., Walawander A. , Eron J.J., Fichtenbaum C.J., Pettinelli C., Neath D., Ferguson E., Saah A.J., Gerber J.G. (2004). Comparison of two indinavir\/ritonavir regimens in the treatment of HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 37:1358\u20131366","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"9032_CR41","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1097\/00002030-200012220-00008","volume":"14","author":"X.J. Zhou","year":"2000","unstructured":"Zhou X.J., Havlir D.V., Richman D.D., Acosta E.P., Hirsch M., Collier A.C., Tebas P., Sommadossi J.P. (2000). Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. Aids 14:2869\u20132876","journal-title":"Aids"},{"key":"9032_CR42","doi-asserted-by":"crossref","first-page":"F95","DOI":"10.1097\/00002030-199910010-00001","volume":"13","author":"R.P. Heeswijk van","year":"1999","unstructured":"van Heeswijk R.P., Veldkamp A.I., Hoetelmans R.M., Mulder J.W., Schreij G., Hsu A., Lange J.M., Beijnen J.H., Meenhorst P.L. (1999).The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. Aids 13:F95\u201399","journal-title":"Aids"},{"key":"9032_CR43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00126334-200103010-00003","volume":"26","author":"D.M. Burger","year":"2001","unstructured":"Burger D.M., Hugen P.W., Aarnoutse R.E., Dieleman J.P., Prins J.M., van der Poll T., ten Veen J.H., Mulder J.W., Meenhorst P.L., Blok W.L., van der Meer J.T., Reiss P., Lange J.M. (2001). A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J. Acquir. Immune Defic. Syndr. 26:218\u2013224","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"9032_CR44","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/AAC.45.1.236-242.2001","volume":"45","author":"T.N. Kakuda","year":"2001","unstructured":"Kakuda T.N., Page L.M., Anderson P.L., Henry K., Schacker T.W., Rhame F.S., Acosta E.P., Brundage R.C., Fletcher C.V. (2001). Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob. Agents Chemother. 45:236\u2013242","journal-title":"Antimicrob. Agents Chemother."},{"key":"9032_CR45","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1592\/phco.19.9.708.31544","volume":"19","author":"E.P. Acosta","year":"1999","unstructured":"Acosta E.P., Henry K., Baken L., Page L.M., Fletcher C.V. (1999). Indinavir concentrations and antiviral effect. Pharmacotherapy 19:708\u2013712","journal-title":"Pharmacotherapy"},{"key":"9032_CR46","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1128\/AAC.48.9.3226-3232.2004","volume":"48","author":"C. Csajka","year":"2004","unstructured":"Csajka C., Marzolini C., Fattinger K., Decosterd L.A., Telenti A., Biollaz J., Buclin T. (2004). Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 48:3226\u20133232","journal-title":"Antimicrob. Agents Chemother."},{"key":"9032_CR47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/135965350300800407","volume":"8","author":"R.E. Aarnoutse","year":"2003","unstructured":"Aarnoutse R.E., Wasmuth J.C., Fatkenheuer G., Schneider K., Schmitz K., de Boo T.M., Reiss P., Hekster Y.A., Burger D.M., Rockstroh J.K. (2003). Administration of indinavir and low-dose ritonavir (800\/100\u00a0mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antivir. Ther. 8:309\u2013314","journal-title":"Antivir. Ther."},{"key":"9032_CR48","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1198\/016214505000000664","volume":"100","author":"S. Sisson","year":"2005","unstructured":"Sisson S. (2005). Trans-dimensional Markov chains: a decade of progress and future perspectives. J. Am. Statis. Assoc. 100:1077\u20131089","journal-title":"J. Am. Statis. Assoc."}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-006-9032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-006-9032-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-006-9032-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:04:14Z","timestamp":1683590654000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-006-9032-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,27]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,12]]}},"alternative-id":["9032"],"URL":"https:\/\/doi.org\/10.1007\/s10928-006-9032-2","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,27]]}}}